Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: A prospective, controlled clinical study

Current Eye Research

Volumn 35, Issue 2, 2010, Pages 91-98

  Artunay, Ozgur ^a   Yuzbasioglu, Erdal ^a   Rasier, Rifat ^a   Sengul, Alper ^a   Bahcecioglu, Halil ^a  

^a ISTANBUL BILIM UNIVERSITY   (Turkey)

Author keywords

Bevacizumab; Central serous chorioretinopathy; Choroid; Intravitreal injection; Macula

Indexed keywords

BEVACIZUMAB;

ADULT; ARTICLE; CENTRAL SEROUS RETINOPATHY; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFECT; FEMALE; HUMAN; MALE; MORPHOLOGY; OPTICAL TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA FOVEA; SINGLE DRUG DOSE; THICKNESS; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE; VISION; VISUAL ACUITY;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CAPILLARY PERMEABILITY; CENTRAL SEROUS CHORIORETINOPATHY; FEMALE; FLUORESCEIN; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL VESSELS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 76749090086     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713680903428306     Document Type: Article

References (44)

1. Spitnaz M. Pathogenesis of central serous chorioretinopathy. A new working hypotheses. Graefes Arch Clin Exp Ophthalmol 1986;224:321-324.
2. Von Graefe A. Central recurrent retinitis. Graefes Arch Clin Exp Ophthalmol 1866;12:211-215.
3. Akiyama K, Kawamura M, Ogata T, et al. Retinal vascular loss in idiopathic central serous chorioretinopathy with bullous retinal detachment. Ophthalmology 1987;94:1605-1609.
4. Schatz H, Osterloh MD, McDonald HR, et al. Development of retinal vascular leakage and cystoid macular oedema secondary to central serous chorioretinopathy. Br J Ophthalmol 1993;77:744-746.
5. Ie D, Yannuzzi LA, Spaide RF, et al. Subretinal exudative deposits in central serous chorioretinopathy. Br J Ophthalmol 1993;77:349-353.
6. Sharma T, Badrinath SS, Gopal L, et al. Subretinal fibrosis and nonrhegmatogenous retinal detachment associated with multifocal central serous chorioretinopathy. Retina 1998;18:23-29.
7. Imasawa M, Ohshiro T, Gotoh T, et al. Central serous chorioretinopathy following vitrectomy with intravitreal triamcinolone acetonide for diabetic macular oedema. Acta Ophthalmol Scand 2005;83:132-133.
8. Taban M, Boyer DS, Thomas EL, et al. Chronic central serous chorioretinopathy: Photodynamic therapy. Am J Ophthalmol 2004;137:1073-1080.
9. Yoshioka H, Katsume Y, Akune H. Experimental central serous chorioretinopathy in monkey eyes (fluorescein angiographic findings). Ophthalmologica 1982;185:168-178. (Pubitemid 12031626)
10. Marmor MF. New hypotheses on the pathogenesis and treatment of serous retinal detachment. Graefes Arch Clin Exp Ophthalmol 1988;226:548-552.
11. Guyer DR, Yannuzzi LA, Slakter JS, et al. Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol 1994;112:1057-1062.
12. Prunte C, Flammer J. Choriodal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 1996;121:26-34.
13. Piccolino FC, Borgia L, Zinicola E, et al. Indocyanine green angiographic findings in central serous chorioretinopathy. Eye 1995;9:324-332.
14. Spaide RF, Hall L, Haas A, et al. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 1996;16:203-213.
15. Scheider A, Nasemann JE, Lund OE. Fluorescein and indocyanine green angiographies of central serous choroidopathy by scanning laser ophthalmoscopy. Am J Ophthalmol 1993;115:50-56.
16. Guyer DR, Yannuzzi LA, Slakter JS, et al. Digital indocyanine- green videoangiography of occult choroidal neovascularization. Ophthalmology 1994;101:1727-1735.
17. Castro-Correia J, Coutinho MF, Rosas V, et al. Long-term follow-up of central serous retinopathy in 150 patients. Doc Ophthalmol 1992;81:379-386.
18. Chan WM, Lai TYY, Lai RYK, et al. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy one-year results of a randomized controlled trial. Ophthalmology 115:1756-1765.
19. Azad RV, Rani A, Pal N, et al. Current and future role of photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol 2005;139:393-394.
20. Gass JD. Photocoagulation treatment of idiopathic central serous choroidopathy. Trans Am Acad Ophthalmol Otolaryngol 1977;83:456-467.
21. Von Ruckmann A, Fitzke FW, Fan J, et al. Abnormalities of fundus autofluorescence in central serous retinopathy. Am J Ophthalmol 2002;133:780-786.
22. Levine R, Brucker AJ, Robinson F. Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography. Ophthalmology 1989;96:854-859.
23. Swante P, Peter H, Sylvie J, et al. Ultrastructural findings in primate eye after intravitreal injection of bevacimuzab. Am J Ophthalmol 2007;143:995-1002.
24. Peters S, Julien S, Heiduschka P, et al. Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. Br J Ophthalmol 2007;91: 827-831.
25. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to agerelated macular degeneration. Retina 2006;26:383-390. (Pubitemid 44197628)
26. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
27. Wang M, Munch IC, Hasler PW, et al. Central serous chorioretinopathy. Review. Acta Ophthalmol Scand 2008;86:126-145.
28. Deissler H, Deissler H, Lang S, Lang GE. VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis) in microvascular retinal endothelial cells. Br J Ophthalmol 2008;92:839-843.
29. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26:999-1005.
30. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335.
31. Spandau UH, Ihloff AK, Jonas JB. Intravitreal bevacizumab treatment of macular oedema due to central retinal vein occlusion. Acta Ophthalmol Scand 2006;84:555-556.
32. Qaum T, Xu Q, Joussen AM, et al. VEGF-initiated bloodretinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001;42:2408-2413
33. Torres-Soriano ME, Aguirre GG, Kon-Jara V, et al. Pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (Case reports). Graefes Arch Clin Exp Ophthalmol 2008;246:1235-1239.
34. Golshahi A, Klingmuller D, Holz FG, et al. Ketoconazole in the treatment of idiopathic central serous chorioretinopathy. Meeting Abstract 9.22.2004; Jahrestagung der DOG Deutsche Ophthalmologische Gesellschaft e.V. 23; Berlin.
35. Meyerle CB, Bailey Freund K, Bhatnagar P, et al. Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. Retina 2007;27:943-946.
36. Niegel MF, Schrage NF, Christmann S, et al. Intravitreal bevacizumab for chronic central serous chorioretinopathy. Ophthalmologe 2008 Jan 24 (Epub ahead of print)
37. Battaglia Parodi M, Da Pozzo S, Ravalico G. Photodynamic therapy in chronic central serous chorioretinopathy. Retina 2003;23:235-237.
38. Canakis C, Livir-Rallatos C, Panayiotis Z, et al. Ocular photodynamic therapy for serous macular detachment in the diffuse retinal pigment epitheliopathy variant of idiopathic central serous chorioretinopathy. Am J Ophthalmol 2003;136:750-752.
39. Cardillo Piccolino F, Eandi CM, Ventre L, et al. Photodynamic therapy for chronic central serous chorioretinopathy. Retina 2003;23:752-763.
40. Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine gren angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: A pilot study. Retina 2003;23:288-298.
41. Chan WM, Lam DS, Lai TY, et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: A novel treatment at the primary disease level. Br J Ophthalmol 2003;87:1453-1458.
42. Chan WM, Timothy YY, Ricky YK, et al. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy. Retina 2008;28:85-94.
43. Cardillo Piccolino F, Eandi CM, Ventre L, et al. Photodynamic therapy for chronic central serous chorioretinopathy. Retina 2003;23:752-763.
44. Chan WM, Lam DS, Lai TY, et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: A novel treatment at the primary disease level. Br J Ophthalmol 2003;87:1453-1458.